Search - tctmd.com

Displaying 281 - 300 of 348

Sort: Relevancy | Date

News Daily News

Burden of Anticoagulation Can Be Reduced in Some Patients With Mechanical Valves

L.A. McKeown

June 12, 2018

News Features

The M Word: Is Routine Transfemoral PCI Defensible in 2018?

Todd Neale

June 08, 2018

News Conference News EAS 2018

EAS Consensus Document Examines Safety of Statins Beyond Muscle Symptoms

Yael L. Maxwell

May 11, 2018

News Daily News

FDA Advisory Panel Says Celecoxib Is as Safe for Heart as Ibuprofen and Naproxen

Michael O'Riordan

April 25, 2018

News Daily News

Time for Guidelines to Recommend ARBs Over ACE Inhibitors?

Shelley Wood

March 29, 2018

News Conference News ACC 2018

Reducing Co-payments for P2Y12 Inhibitors Upped Ticagrelor Use but Didn’t Budge MACE: ARTEMIS

Caitlin E. Cox

March 11, 2018

News Daily News

CABG Bests PCI for 5-Year Survival in Biggest Analysis Yet, With Options for Left Main Disease

Yael L. Maxwell

March 08, 2018

News Daily News

REAL PTX: Head-to-Head DCB, DES Data in PAD Show Trend Favoring Stenting at 36 Months

L.A. McKeown

February 11, 2018

News Daily News

Nonstatin Use and Expenditures Are Up Despite the Dearth of Evidence Supporting Efficacy

Yael L. Maxwell

January 29, 2018

News Conference News AHA 2017

Global Improvement in ACS Care Seen With Regional Clinical Pathway Implementation

Yael L. Maxwell

November 27, 2017

News Opinion Editor's Corner TCT 2017

My Takeaways From TCT 2017: Show Up, Keep It Civil, and Bring Your Best Self

Shelley Wood

November 22, 2017

News Conference News AHA 2017

TRICS III: Restrictive Red-Cell Transfusion Noninferior to Liberal Use in Cardiac Surgery

Shelley Wood

November 12, 2017

News Conference News TCT 2017

TCT 2017: High Hopes in Denver for Complex PCI, Shorter DAPT Durations, TAVR Costs, and More

Shelley Wood

October 20, 2017

News Daily News

Alirocumab Ban Reversed, New Trial Ordered in PCSK9 Patent Dispute

Michael O'Riordan

October 10, 2017

News Conference News ESC 2017

VIVA: Could Population-Wide Screening Trial for AAA, PAD, and Hypertension Save Lives at Low Cost?

Shelley Wood

August 28, 2017

News Conference News ESC 2017

European Societies Issue New Valvular Heart Disease Guidelines, With Important Shifts

Shelley Wood

August 27, 2017

News Daily News

Evolocumab Not Cost-Effective at Current List Price

Michael O'Riordan

August 23, 2017

News Daily News

TAVR in the US: Regional Variations in Numbers, Outcomes

Michael O'Riordan

August 22, 2017

Studies Supporting Device Modifications Weak, Often Based on Surrogate Endpoints

News Daily News

FDA Clearance of Modified Devices Relies Heavily on Weak Studies, Surrogate Endpoints

Michael O'Riordan

August 16, 2017

News Daily News

Long-term Ticagrelor Post-MI of ‘Intermediate Value’: Cost-Effectiveness Study

Leah Lawrence

July 24, 2017

Advertisement

Burden of Anticoagulation Can Be Reduced in Some Patients With Mechanical Valves

The M Word: Is Routine Transfemoral PCI Defensible in 2018?

EAS Consensus Document Examines Safety of Statins Beyond Muscle Symptoms

FDA Advisory Panel Says Celecoxib Is as Safe for Heart as Ibuprofen and Naproxen

Time for Guidelines to Recommend ARBs Over ACE Inhibitors?

Reducing Co-payments for P2Y12 Inhibitors Upped Ticagrelor Use but Didn’t Budge MACE: ARTEMIS

CABG Bests PCI for 5-Year Survival in Biggest Analysis Yet, With Options for Left Main Disease

REAL PTX: Head-to-Head DCB, DES Data in PAD Show Trend Favoring Stenting at 36 Months

Nonstatin Use and Expenditures Are Up Despite the Dearth of Evidence Supporting Efficacy

Global Improvement in ACS Care Seen With Regional Clinical Pathway Implementation

My Takeaways From TCT 2017: Show Up, Keep It Civil, and Bring Your Best Self

TRICS III: Restrictive Red-Cell Transfusion Noninferior to Liberal Use in Cardiac Surgery

TCT 2017: High Hopes in Denver for Complex PCI, Shorter DAPT Durations, TAVR Costs, and More

Alirocumab Ban Reversed, New Trial Ordered in PCSK9 Patent Dispute

VIVA: Could Population-Wide Screening Trial for AAA, PAD, and Hypertension Save Lives at Low Cost?

European Societies Issue New Valvular Heart Disease Guidelines, With Important Shifts

Evolocumab Not Cost-Effective at Current List Price

TAVR in the US: Regional Variations in Numbers, Outcomes

FDA Clearance of Modified Devices Relies Heavily on Weak Studies, Surrogate Endpoints

Long-term Ticagrelor Post-MI of ‘Intermediate Value’: Cost-Effectiveness Study

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content